Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 2110-2111, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mastropaolo, W.
Right arrow Articles by Miller, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mastropaolo, W.
Right arrow Articles by Miller, E. L.

Clinical Chemistry, Vol 32, 2110-2111, Copyright © 1986 by American Association for Clinical Chemistry

Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation

W Mastropaolo, Z Fernandez and EL Miller

CA-125 is a glycoprotein associated with various ovarian tumors. A commercial radioimmunoassay involving a monoclonal antibody is available for it. In our laboratory, a normal-value study was conducted as part of a routine evaluation of this assay. One healthy subject had a serum CA-125 concentration greater than 300 kU/L, more than eightfold the upper limit of normal (35 kU/L). This increase, which coincided with the onset of the menstrual period, subsided to within the normal range by the end of the menstrual cycle. The half-life of CA-125, calculated from this decrease, was 6.4 days. Similar observations were made in the same subject over several menstrual cycles. Results of clinical and ultrasound examinations of the subject for ovarian tumors were negative. No clinical evidence of malignancy was present eight months after the initial discovery of an increased CA-125. None of the other 39 healthy subjects had a CA-125 value greater than 51 kU/L. Five of these subjects had CA-125 determined several times during their menstrual cycles; none exhibited pronounced variations in CA-125 concentrations. Evidently CA-125 can be extremely increased in a healthy woman, and possible effects of the menstrual period on serum CA- 125 concentrations should be considered in pre-menopausal patients.


The following articles in journals at HighWire Press have cited this article:


Home page
 Cancer Res.Home page
M. Chatterjee, S. Mohapatra, A. Ionan, G. Bawa, R. Ali-Fehmi, X. Wang, J. Nowak, B. Ye, F. A. Nahhas, K. Lu, et al.
Diagnostic Markers of Ovarian Cancer by High-Throughput Antigen Cloning and Detection on Arrays
Cancer Res., January 15, 2006; 66(2): 1181 - 1190.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. T. Baron, C. H. Boardman, J. M. Lafky, A. Rademaker, D. Liu, D. A. Fishman, K. C. Podratz, and N. J. Maihle
Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 306 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
G. G. Bon, P. Kenemans, J. J. Dekker, P. G. Hompes, R. A. Verstraeten, G. J. van Kamp, and J. Schoemaker
Fluctuations in CA 125 and CA 15–3 serum concentrations during spontaneous ovulatory cycles
Hum. Reprod., February 1, 1999; 14(2): 566 - 570.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Lokich, C. G. Kreger, R. A. Murden, L. A. Hassell, J. Van den Ende, W. Schroyens, E. Van den Enden, C. Putterman, and E. Ben-Chetrit
Clinical Problem-Solving: Hypereosinophilic Syndrome
N. Engl. J. Med., February 22, 1996; 334(8): 538 - 540.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.